Novartis has signed a licensing and equity agreement with Boston Pharmaceuticals to develop three anti-infective programmes for the potential treatment of antibiotic resistant gram-negative infections.
Under the terms of the agreement, Boston Pharmaceuticals gains worldwide rights to the drug candidates, which are part of the Novartis Infectious Diseases portfolio.
The licensed programmes are comprised of two candidates, LYS228 and IID572, which target carbapenem-resistant enterobacteriaceae (CRE), as well as MAK181 to treat Pseudomonas infections.
LYS228 is a monobactam currently in clinical development stage. The drug candidate is reported to have shown activity against CRE with resistance by serine beta-lactamases (SBLs) and metallo beta-lactamases (MBLs).
IID572 is a beta-lactamase inhibitor for use in combination with beta-lactam antibiotics against difficult-to-treat infections caused due to a variety of CRE, while MAK181 is an oral LpxC inhibitor for Pseudomonas infections.
Novartis Institutes for BioMedical Research president Jay Bradner said: “The need for new antibiotics that address drug resistant bacteria is clear and we are pleased to find a partner in Boston Pharmaceuticals who will dedicate the appropriate expertise and resources for the further development and commercialisation of these programmes.
“Drug discovery and development is a team sport and this agreement is part of our strategy to partner with like-minded innovators outside of our walls to further develop new innovative medicines focused on addressing global health challenges.”
Boston Pharmaceuticals will make an upfront payment to Novartis, which is also eligible for royalties and milestone payments on any successfully commercialised drugs.
Boston Pharmaceuticals CEO Robert Armstrong said: “The acquisition of these three novel anti-infective candidates further demonstrates our commitment to addressing unmet medical needs in order to benefit patients. We look forward to building on this quality research as we advance these candidates.”